1. OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS. (June 2019) Authors: Werth, Victoria; Pearson, David; Owaka, Joyce; Feng, Rui; Concha, Josef Simon; Patel, Basil; Hejazi, Emily; Cornwall, Caitlin; Constantine, Scott; Dgetluck, Nancy; White, Barbara Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single‐center case‐control study. (23rd October 2020) Authors: Zeidi, Majid; Chen, Kristen L.; Patel, Basil; Ravishankar, Adarsh; Lim, Rachel; Werth, Victoria P. Journal: Journal of cutaneous pathology Issue: Volume 48:Number 3(2021) Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗